Page last updated: 2024-11-06

5-iodouracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Iodouracil is a synthetic analog of uracil, a pyrimidine base found in DNA and RNA. It is a potent inhibitor of DNA synthesis and is used in research as a tool to study DNA replication and repair. 5-Iodouracil is also used as a therapeutic agent in the treatment of certain types of cancer. It is synthesized by reacting uracil with iodine in the presence of a catalyst. 5-Iodouracil is incorporated into DNA during replication and can disrupt DNA synthesis by acting as a chain terminator. It can also induce mutations by base pairing with adenine instead of guanine. These properties make 5-Iodouracil a valuable tool for studying DNA replication and repair mechanisms. It is also used as a therapeutic agent in the treatment of certain types of cancer, such as leukemia and lymphoma. 5-Iodouracil is studied extensively in cancer research because of its ability to inhibit DNA synthesis and induce mutations. Its potential therapeutic applications are also being investigated.'

5-iodouracil: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-iodouracil : An organoiodine compound consisting of uracil having an iodo substituent at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69672
CHEMBL ID1173
CHEBI ID43636
SCHEMBL ID7884
MeSH IDM0140079

Synonyms (67)

Synonym
AC-19702
5-iodopyrimidine-2,4-diol
STK697694
5909-21-7
5-iodo-1h-pyrimidine-2,4-dione
2,3h)-pyrimidinedione, 5-iodo-
696-07-1
wln: t6mvmvj fi
5-iodouracil
nsc-57848
uracil, 5-iodo-
nsc57848
inchi=1/c4h3in2o2/c5-2-1-6-4(9)7-3(2)8/h1h,(h2,6,7,8,9
5-iodopyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 5-iodo-
IUR ,
5-iodouracil, 98%
DB03554
nsc 57848
einecs 211-788-2
ai3-50390
uracil, 5-iodo- (van)
bdbm50124203
2,4-dihydroxy-5-iodopyrimidine
CHEBI:43636 ,
CHEMBL1173 ,
I0219
A9206
5-iodo-1,3-dihydropyrimidine-2,4-dione
unii-h59brk500m
h59brk500m ,
4-hydroxy-5-iodopyrimidin-2(1h)-one
STK577648
AKOS015963410
AKOS005203195
AKOS005503329
5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione
PS-4031
AM20100652
EPITOPE ID:138110
FT-0620521
MLS006011387
smr002529992
SCHEMBL7884
5-iodopyrimidine-2,4(1h, 3h)-dione
5-iodo-uracil
5-iodo uracil
DTXSID3061009
5-iodo-2,4-dihydroxypyrimidine
W-104615
BBL035414
STR02045
5-iodo-2,4(1h,3h)-pyrimidinedione #
STL415952
mfcd00006020
J-802152
AKOS026732157
CS-W001983
GS-6885
SR-01000945135-1
sr-01000945135
SY015873
Q27094489
n-(4-methoxybenzyl-n,n-dimethyl-n-2-pyridylethylenediaminemonohydrochloride
PD006817
EN300-96043
Z1269147233

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" An average absorption rate constant of 122 +/- 34 micrograms/cm2-hr was obtained from the XRF measurements on four rats."( Noninvasive in vivo percutaneous absorption measurements using X-ray fluorescence.
Ferguson, E; Jay, M; Robertson, JD; Stalker, DJ, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.22000.00040.908610.0000AID56039
Dihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)IC50 (µMol)0.22000.01400.13080.2200AID56039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
purine nucleobase catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
pyrimidine nucleobase catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
thymine catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
uracil catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
thymidine catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
CMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dCMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
beta-alanine biosynthetic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
UMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dUMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dihydropyrimidine dehydrogenase (NADP+) activityDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
protein homodimerization activityDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
metal ion bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
flavin adenine dinucleotide bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
NADP bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
4 iron, 4 sulfur cluster bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
uracil bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasmDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
cytosolDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
cytosolDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID96642Cytostatic activity against proliferation of L1210/0 cells (murine leukemia L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID165909Cytostatic activity against proliferation of Raji/TK cells (deoxythymidine kinase deficient Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID1135817Retention time of the compound by liquid chromatography1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides.
AID96643Cytostatic activity against proliferation of L1210/BdU cells (deoxythymidine kinase deficient L1210 cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID165908Cytostatic activity against proliferation of Raji/0 cells (human lymphoblast Raji cells)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Synthesis, structure, and antitumor and antiviral activities of a series of 5-halouridine cyclic 3',5'-monophosphates.
AID56039Inhibitory activity against dihydropyrimidine dehydrogenase (DPD)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (31.82)18.7374
1990's12 (27.27)18.2507
2000's14 (31.82)29.6817
2010's4 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.28 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]